GlassScriptPhysician profile
Xuan N Huang
NPI 1639308232
$9,245.23
in general payments reported to CMS, 2019-2025
32 companies · $2,478 in 2025
The $2,478 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $321 · 2020: $3,506 · 2021: $1,069 · 2022: $461 · 2023: $930 · 2024: $480 · 2025: $2,478.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,928 · Travel and Lodging: $766 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $194.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,928.07 |
| Travel and Lodging | $765.84 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $193.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,121.54 | 2020-2025 | |
| Merz North America, INC. | $2,041.01 | 2023-2025 | Xeomin |
| Beigene USA, INC. | $1,749.96 | 2020-2025 | Brukinsa |
| Allergan, INC. | $1,520.00 | 2021-2023 | |
| E.R. Squibb & Sons, L.L.C. | $253.23 | 2019-2024 | Opdualag |
| Seagen INC. | $239.34 | 2023 | Tukysa |
| Incyte Corporation | $185.61 | 2020-2025 | Zynyz, Monjuvi |
| Jazz Pharmaceuticals INC. | $125.23 | 2023 | |
| Sirtex Medical INC | $118.39 | 2024 | Sir-Spheres Microspheres |
| Taiho Oncology, INC. | $117.65 | 2019 | |
| Abbvie INC. | $103.18 | 2023-2025 | |
| Daiichi Sankyo INC. | $97.33 | 2024-2025 | Enhertu, Injectafer |
| Merck Sharp & Dohme LLC | $81.50 | 2019-2025 | Keytruda |
| Galderma Laboratories, L.P. | $77.23 | 2024 | |
| Janssen Biotech, INC. | $55.14 | 2019-2024 | Erleada, Darzalex, Carvykti |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $37.97 | 2025 | Cabometyx |
| Tempus Ai, INC | $29.95 | 2024 | |
| Alexion Pharmaceuticals, INC. | $26.17 | 2025 | Ultomiris |
| Bard Access Systems, INC. | $24.61 | 2019 | |
| Novartis Pharmaceuticals Corporation | $23.84 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $22.25 | 2024 | Alunbrig |
| Karyopharm Therapeutics INC. | $20.87 | 2024 | Xpovio |
| Amgen INC. | $20.31 | 2019 | |
| Servier Pharmaceuticals LLC | $19.67 | 2024 | |
| Sumitomo Pharma America, INC. | $19.55 | 2025 | Orgovyx |
| Sobi, INC | $19.49 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.14 | 2019 | |
| Genmab U.S., INC. | $16.55 | 2025 | Tivdak |
| Pfizer INC. | $16.09 | 2024 | |
| Stemline Therapeutics INC. | $14.97 | 2024 | Orserdu |
| Gilead Sciences, INC. | $14.91 | 2025 | |
| Genentech USA, INC. | $14.55 | 2024 | Tecentriq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Xuan Huang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.